- ISIN
- US9495031067
- Sector
- Healthcare
- Industry
- Pharmaceutical Retailers
- IPO Date
- Feb 21, 2025
Highlights
- Market Cap
- $13.28M
- Enterprise Value
- -$3.51B
- EPS (TTM)
- -$215.19
- Total Revenue (TTM)
- $487.92M
- Gross Profit (TTM)
- $385.33M
- EBITDA (TTM)
- $902.31M
- Year Range
- $2.48 - $97.50
- ROA (TTM)
- -51.47%
- ROE (TTM)
- -62.13%
- Avg. Volume (1M)
- 48K
- Avg. Volume Value (1M)
- $157.78K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
MEDS Performance Chart
DataMEDS AI, Inc. (MEDS) is down 82.1% since the beginning of the year. At $4 per share, MEDS is trading 96.3% below its 52-week high of $98.
Loading charts...
Returns By Period
DataMEDS AI, Inc. (MEDS) has returned -82.08% so far this year and -93.05% over the past 12 months.
DataMEDS AI, Inc.
- 1D
- 1.70%
- 1M
- 15.48%
- 6M
- -81.97%
- YTD
- -82.08%
- 1Y
- -93.05%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -94.54%
Benchmark (S&P 500 Index)
- 1D
- -0.14%
- 1M
- 0.35%
- 6M
- 9.07%
- YTD
- 9.55%
- 1Y
- 18.85%
- 3Y*
- 18.24%
- 5Y*
- 11.19%
- 10Y*
- 13.18%
- ALL TIME*
- 8.09%
MEDS Monthly Returns History
Based on dividend-adjusted daily data since Feb 21, 2025, MEDS's average daily return is -0.34%, while the average monthly return is -14.95%.
Historically, 28% of months were positive and 72% were negative. The best month was Mar 2025 with a return of +60.0%, while the worst month was Mar 2026 at -59.7%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 7 months.
On a daily basis, MEDS closed higher 37% of trading days. The best single day was Oct 24, 2025 with a return of +185.4%, while the worst single day was May 8, 2025 at -30.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -10.24% | -33.35% | -59.67% | 14.11% | -37.82% | -9.36% | 15.48% | -82.08% | |||||
| 2025 | -37.93% | 60.00% | 0.46% | -53.69% | -51.81% | -10.40% | 41.72% | -27.88% | -21.18% | -14.17% | -33.43% | -90.82% |
Benchmark Metrics
DataMEDS AI, Inc. has an annualized alpha of -66.56%, beta of 1.41, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since February 21, 2025.
- This stock participated in 416.59% of S&P 500 Index downside but only -169.33% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -66.56%
- Beta
- 1.41
- R²
- 0.01
- Upside Capture
- -169.33%
- Downside Capture
- 416.59%
Return for Risk
Risk / Return Rank
MEDS ranks 21 for risk / return — below 21% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for DataMEDS AI, Inc. (MEDS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MEDS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.85 | ||
| Sortino ratioReturn per unit of downside risk | -2.47 | ||
| Omega ratioGain probability vs. loss probability | 0.96 | 1.27 | -0.31 |
| Calmar ratioReturn relative to maximum drawdown | -0.96 | 2.08 | -3.04 |
| Martin ratioReturn relative to average drawdown | -1.23 | 8.97 | -10.20 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the DataMEDS AI, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the DataMEDS AI, Inc. was 98.93%, occurring on Jul 17, 2026. The portfolio has not yet recovered.
The current DataMEDS AI, Inc. drawdown is 98.56%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-98.93%Jul 2026 | 1y 3mo | — | 1y 4moMar 2025 - now | — |
-41.61%Mar 2025 | 18d | 9d | 27dFeb 2025 - Mar 2025 | 2025 selloff2025 |
Drawdown Indicators
| MEDS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.93% | -56.78% | -42.15% |
Max Drawdown (1Y)Largest decline over 1 year | -96.94% | -9.10% | -87.84% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -98.56% | -1.46% | -97.10% |
Average DrawdownAverage peak-to-trough decline | -77.33% | -10.70% | -66.63% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 75.63% | 2.11% | +73.52% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of DataMEDS AI, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how DataMEDS AI, Inc. is priced in the market compared to other companies in the Pharmaceutical Retailers industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for MEDS relative to other companies in the Pharmaceutical Retailers industry. Currently, MEDS has a P/S ratio of 1.4. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for MEDS in comparison with other companies in the Pharmaceutical Retailers industry. Currently, MEDS has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with MEDS
Add DataMEDS AI, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with MEDS